Related Experiment Video
Updated: May 3, 2026
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
38.4K
[Treatment of Behçet's disease].
C Comarmond1, B Wechsler1, P Cacoub1
1Service de médecine interne et d'immunologie clinique, centre de référence des maladies autoimmunes rares, DHU i2B, inflammation, immunopathologie, biothérapie, université Pierre-et-Marie-Curie, groupe hospitalier Pitié-Salpêtrière, AP-HP, Paris 6, Paris, France.
La Revue De Medecine Interne
|January 21, 2014
Summary
Behçet's disease (BD) is a complex vasculitis requiring tailored treatment. Future therapies may offer targeted approaches for refractory cases, improving patient outcomes.
Area of Science:
- Rheumatology
- Immunology
- Vascular Medicine
Background:
- Behçet's disease (BD) is a systemic vasculitis with diverse clinical manifestations.
- Current treatments include colchicine, NSAIDs, corticosteroids, and immunosuppressants for severe cases.
- Refractory disease, relapses, and organ damage remain significant challenges in BD management.
Purpose of the Study:
- To review the current understanding of Behçet's disease pathogenesis.
- To explore emerging therapeutic strategies targeting specific pathways in BD.
- To discuss the potential of novel immunomodulatory and targeted therapies.
Main Methods:
- Literature review of Behçet's disease pathogenesis and treatment.
- Analysis of recent advancements in understanding BD mechanisms.
- Evaluation of novel therapeutic targets and drug development.
Main Results:
- Pathogenic mechanisms of BD are increasingly understood.
- Immunomodulatory and targeted therapies show promise for specific pathways.
- These novel approaches may offer alternatives to current non-specific immunosuppressants.
Conclusions:
- Understanding BD pathogenesis is key to developing targeted therapies.
- Emerging immunomodulatory drugs offer potential for specific pathway interference.
- Novel targeted immunosuppressive therapies represent a future direction for BD treatment.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
1.1K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
1.1K
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
692
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
692
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
880
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880
01:29Drugs for Treatment of Ulcerative Colitis in IBD
705
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
705
01:26Peptic Ulcer Disease IV: Management
807
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
807
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
755
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755